DOCSLIB.ORG

Discerning the Role of Krüppel-Like Factor 4 in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discerning the Role of Krüppel-Like Factor 4 in Breast Cancer DISCERNING THE ROLE OF KRÜPPEL-LIKE FACTOR 4 IN BREAST CANCER by JENNIFER L. YORI Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Dr. Ruth A. Keri Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY May, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of ______________________________________________________ candidate for the ________________________________degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. DEDICATION This work is dedicatied to Beverly Ann McMillan for all that she taught me and Fiona Campbell Yori for all that she teaches me everyday. iii TABLE OF CONTENTS List of Tables vii List of Figures viii Acknowledgements x Abbreviations xii Abstract 1 Chapter I INTRODUCTION, REVIEW OF THE LITERTURE, AND 3 STATEMENT OF PURPOSE 1.1 Molecular/Histopathological subtypes and cellular origin of 3 breast cancer 1.1.1 Luminal breast cancer 5 1.1.2 HER2/ERRB2 breast cancer 6 1.1.3 Basal-like breast cancer 8 1.1.4 Comparison of mouse models and human tumors generate a 10 new molecular subtype 1.2 Metastasis, epithelial-to mesenchymal transition (EMT) and 12 the cancer stem cell theory 1.2.1 The epithelial-to-mesenchymal transition 13 1.2.1.1 Transcriptional regulation of EMT 15 1.2.2 The cancer stem cell theory 19 1.2.2.1 Cancer stem cells and EMT 21 1.2.2.2 iPS cells 23 iv 1.3 Krüppel-like factor 4 (KLF4) 24 1.3.1 The Sp1/Krüppel-like factor family 24 1.3.2 Krüppel-like factor 4 (KLF4) 26 1.3.2.1 Structure and regulation 26 1.3.2.2 Mechanisms of activation and repression 28 1.3.3 Function of KLF4 in normal biological processes 30 1.3.3.1 KLF4 as a regulator of development and differentiation 30 1.3.3.2 KLF4 regulation of proliferation and apoptosis 31 1.3.4 The role of KLF4 during carcinogenesis 34 1.3.4.1 KLF4 as tumor suppressor 34 1.3.4.2 KLF4 as an oncogene 35 1.3.4.3 The role of KLF4 in breast cancer and metastasis 35 1.3.4.4 Krüppel-like factors, EMT and metastasis 37 1.4 Statement of Purpose 39 Chapter 2 KRÜPPEL-LIKE FACTOR 4 (KLF4) INHIBITS 52 EPITHELIAL-TO-MESENCHYMAL TRANSITION THROUGH REGULATION OF E-CADHERIN GENE EXPRESSION 2.1 Introduction 53 2.2 Materials and Methods 56 2.3 Results 61 2.4 Discussion 67 2.5 Acknowledgements 74 v Chapter 3 KRÜPPEL-LIKE FACTOR 4 INHIBITS TUMORIGENIC 88 PROGRESSION AND METASTASIS IN A MOUSE MODEL OF BREAST CANCER 3.1 Introduction 89 3.2 Materials and Methods 91 3.3 Results 95 3.4 Discussion 101 3.5 Acknowledgements 105 Chapter 4 SUMMARY AND FUTURE DIRECTIONS 120 4.1 Summary 120 4.2 Future directions 121 4.2.1 Pharmacological targeting of KLF4 121 4.2.2 Does TGF-β signaling regulate KLF4 expression during EMT? 130 4.2.3 Can forced expression of KLF4 block TGF-β-induced EMT? 131 4.2.4 Does the TGF-β “switch” during tumorigenesis alter its effect 132 on the regulation of KLF4? 4.2.5 What are the mechanisms by which KLF4 suppresses Snail? 133 4.2.6 Does HER2 signaling regulate KLF4 expression? 134 4.2.7 What is the role of KLF4 in the maintenance and self-renewal 135 of MaSCs and CSCs? References 139 vi LIST OF TABLES Table 1.1 Regulators and Targets of KLF4 48 Table 3.1 Incidence of lung and liver micrometastases in AdGFP-4T1 and 106 AdKLF4-4T1 tumor bearing mice at 21 days post injection vii LIST OF FIGURES Figure 1.1 The link between normal mammary epithelial hierarchy, 41 molecular subtypes, gene expression signatures and clinical markers of breast cancer Figure 1.2 Organization of the human KLF4 gene and protein 43 Figure 1.3 KLF4 is a central player in the regulatory networks modulating 45 EMT and MET during generation of iPSCs and CSCs Figure 2.1 KLF4 is required for the maintenance of mammary epithelial 75 cell morphology Figure 2.2 KLF4 silencing results in loss of acinus formation and 77 decreased proliferation of mammary epithelial cells Figure 2.3 KLF4 is required to sustain E-cadherin expression in non- 79 transformed mammary epithelial cells Figure 2.4 KLF4 binds and activates the E-cadherin promoter 81 Figure 2.5 KLF4 induces expression of E-cadherin protein and a 83 transition to epithelial morphology in the mesenchymal-like MDA-MB-231 breast cancer cells Figure 2.6 KLF4 transcriptional activation of E-cadherin results in 85 decreased migration and invasion of MDA-MB-231 cells Figure 3.1 Loss of KLF4 expression in Her2/Neu-induced mouse 107 mammary tumors Figure 3.2 KLF4 expression inversely correlates with metastatic 110 viii progression Figure 3.3 KLF4 inhibits growth of 4T1 cells 112 Figure 3.4 KLF4 inhibits primary tumor growth of 4T1 cells 114 Figure 3.5 KLF4 overexpression decreases lung and liver micrometastases 116 Figure 3.6 KLF4 inhibits Snail expression in mammary epithelial cells and 118 tumor cells ix ACKNOWLEDGEMENTS It is very rare that one gets the opportunity to spend their time pursuing a career in something they are genuinely passionate about. I am ever grateful to the numerous people in my life who have made this possible. To Dr. John Nilson, who first brought me into the Pharmacology Department, imparting upon me his great words of wisdom, “It doesn‟t matter if you‟re not as smart as everyone else, it just means you have to work harder than everyone else”. His support and advice through my first year of graduate school made me realize this truly was an attainable goal. To Helai Mohammad, who taught me everything I needed to know in order to realize how much I really didn‟t know, I thank you for your persistence and attention to detail, as well as a solid understanding of cloning! I would especially like to thank Dr. Ruth Keri, who upon John‟s departure accepted me into her laboratory, allowing me to work in the area of breast cancer research. As a mentor, she has provided me with the opportunity to develop a research project from the ground up and call it my own. She has challenged me to critically evaluate my own experimental designs and data as well as the scientific literature. In addition, unlike most mentors, she has allowed her students to be an integral part of the grant writing process, contributing at all levels, from suggested experiments to critical review. She is truly a role model for young women in science. I‟m also grateful to my committee members, Dr. Amy Wilson-Delfosse, Dr. Mukesh Jain, and Dr. Noa Noy for their input and guidance. x During my time in the lab, many new members have come as old ones have moved on. Throughout the duration there has been comfort in consistency. To Darcie Seachrist and Kristen Lozada, who have been with me since the beginning and are still there today, I don‟t think I could have endured this journey without your friendships and support. Kris, thank you for teaching me all the ways to manipulate a mouse and for your many hours in the mouse room, especially when I was on maternity leaves. Darcie, your willingness to listen and offer advice, both scientific and personal, is so appreciated. I cannot thank you enough for all the hard work you put in towards the end to help me finish up. I‟d like to also thank several past lab member, including Jonathan Mosley, Erin Milliken, and Melissa Landis, for keeping me excited about science and showing me how it was done. To Monty Johnson, our first post-doc, I owe many thanks. His willingness to share his experience, knowledge and time was really a turning point for me in my graduate career, and I am forever grateful. Finally, I would like to thank my family and friends who have provided me with all the encouragement, love and support I could ever need. Rick and Louise Yori, the best in- laws anyone could ask for, thank you for your generosity and willingness to help, always! Dad, even though you‟ve teased me about being in school since I was five, you‟ve always found a way to let me know how proud you were of me, and that has meant so much.. To my husband Rich, who has helped me raise two wonderful children during these busy years, words alone could never convey my thanks and gratitude for all your sacrifice. Most of all, I would like to thank my mother, who provided me with a true appreciation for education, an understanding of true commitment and strength, and the realization that life is what you alone make of it – Thank you. xi ABBREVIATIONS AI Aromatase inhibitor AKT Protein kinase B APC Adenomatous polyposis coli bHLH Basic helix-loop-helixβ β-TrCP Beta-transducin repeat containing BRCA1 Breast cancer 1, early onset CBP CREB binding protein Cdk Cyclin-dependent kinase CK5/6 Cytokeratin 5/6 CRB3 Crumbs-3 CSC Cancer stem cell CYP1A1 Cytochrome P450 family 1, member A1 EGFR Epidermal growth factor receptor (HER1) EMT Epithelial-to-mesencymal transition ER Estrogen receptor ES Embryonic stem FOXC2 Forkhead box C2 GSK3β Glycogen synthase kinase 3 beta H3K4 Histone H3 lysine 4 HDAC1/2 Histone deacetylase 1/2 xii HDC Histidine decarboxylase HER2 Human epidermal growth factor receptor 2 (ERRB2, NEU) HER3 Human epidermal growth factor receptor 3 hNMSC Human normal mammary stem cell IHC Immunohistochemistry iPSC Induced pluripotent stem cell KLF4/GKLF/EZF Krüppel-like factor 4 / Gut-enriched krüppel-like factor 4 / Epithelial
Load more

Recommended publications
  • Keratin 19 Regulates Cell Shape and Cell-Cell Adhesion of MCF7 Cells While Maintaining E-Cadherin Localization at the Cell Surface
    Keratin 19 regulates cell shape and cell-cell adhesion of MCF7 cells while maintaining E-cadherin localization at the cell surface Welcome to my poster. This is Sarah Alsharif, a PhD student from the biology department. I am glad to present the work our lab has been doing in the breast cancer field. In fact, after lung cancer, breast cancer is the second cause of death in women worldwide (1). It is estimated that every 18 seconds, approximately one new case of breast cancer is documented (2). No one dies due to cancer itself. The death is because of metastasis which takes place when cancer cells leave a breast in which they are formed and reach other sites such as the brain or lung. Our lab is interested in investigating the mechanism behind metastasis of breast cancer. Metastasis is associated with what is called epithelial to mesenchymal transition (EMT), the process characterized by loss of cell to cell adhesion and expression of epithelial markers such as keratin intermediate filament proteins, as you can see in the first three images of cells. Those filaments are keratins and they are critical for the shape and for maintaining mechanical integrity of epithelial cells via cell to cell complexes called desmosomes. Among different keratins, keratin 19 (K19) is highly expressed in many types of cancer including breast cancer, and is correlated with a worse prognosis (3). Consistently, K19 expression has been reported to be significantly higher in metastatic breast cancer tumor cells compared to primary tumors (4). The role of K19 on mechanical properties of cancer cells for cell migration and possible impact on metastasis in breast cancer patients is still unknown.
    [Show full text]
  • Microglia Emerge from Erythromyeloid Precursors Via Pu.1- and Irf8-Dependent Pathways
    ART ic LE S Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways Katrin Kierdorf1,2, Daniel Erny1, Tobias Goldmann1, Victor Sander1, Christian Schulz3,4, Elisa Gomez Perdiguero3,4, Peter Wieghofer1,2, Annette Heinrich5, Pia Riemke6, Christoph Hölscher7,8, Dominik N Müller9, Bruno Luckow10, Thomas Brocker11, Katharina Debowski12, Günter Fritz1, Ghislain Opdenakker13, Andreas Diefenbach14, Knut Biber5,15, Mathias Heikenwalder16, Frederic Geissmann3,4, Frank Rosenbauer6 & Marco Prinz1,17 Microglia are crucial for immune responses in the brain. Although their origin from the yolk sac has been recognized for some time, their precise precursors and the transcription program that is used are not known. We found that mouse microglia were derived from primitive c-kit+ erythromyeloid precursors that were detected in the yolk sac as early as 8 d post conception. + lo − + − + These precursors developed into CD45 c-kit CX3CR1 immature (A1) cells and matured into CD45 c-kit CX3CR1 (A2) cells, as evidenced by the downregulation of CD31 and concomitant upregulation of F4/80 and macrophage colony stimulating factor receptor (MCSF-R). Proliferating A2 cells became microglia and invaded the developing brain using specific matrix metalloproteinases. Notably, microgliogenesis was not only dependent on the transcription factor Pu.1 (also known as Sfpi), but also required Irf8, which was vital for the development of the A2 population, whereas Myb, Id2, Batf3 and Klf4 were not required. Our data provide cellular and molecular insights into the origin and development of microglia. Microglia are the tissue macrophages of the brain and scavenge dying have the ability to give rise to microglia and macrophages in vitro cells, pathogens and molecules using pattern recognition receptors and in vivo under defined conditions.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Tnfa-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer María F
    Published OnlineFirst October 3, 2016; DOI: 10.1158/1078-0432.CCR-16-0970 Cancer Therapy: Clinical Clinical Cancer Research TNFa-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer María F. Mercogliano1, Mara De Martino1, Leandro Venturutti1, Martín A. Rivas2, Cecilia J. Proietti1, Gloria Inurrigarro3, Isabel Frahm3, Daniel H. Allemand4, Ernesto Gil Deza5, Sandra Ares5, Felipe G. Gercovich5, Pablo Guzman 6, Juan C. Roa6,7, Patricia V. Elizalde1, and Roxana Schillaci1 Abstract Purpose: Although trastuzumab administration improved the Results: TNFa overexpression turned trastuzumab-sensitive outcome of HER2-positive breast cancer patients, resistance cells and tumors into resistant ones. Histopathologic findings events hamper its clinical benefits. We demonstrated that TNFa revealed mucin foci in TNFa-producing tumors. TNFa induced stimulation in vitro induces trastuzumab resistance in HER2- upregulation of MUC4 that reduced trastuzumab binding to its positive breast cancer cell lines. Here, we explored the mechanism epitope and impaired ADCC. Silencing MUC4 enhanced trastu- of TNFa-induced trastuzumab resistance and the therapeutic zumab binding, increased ADCC, and overcame trastuzumab and strategies to overcome it. trastuzumab-emtansine antiproliferative effects in TNFa-overex- Experimental Design: Trastuzumab-sensitive breast cancer pressing cells. Accordingly, administration of TNFa-blocking cells, genetically engineered to stably overexpress TNFa,and antibodies downregulated MUC4 and sensitized de novo trastu- de novo trastuzumab-resistant tumors, were used to evaluate zumab-resistant breast cancer cells and tumors to trastuzumab. In trastuzumab response and TNFa-blocking antibodies effective- HER2-positive breast cancer samples, MUC4 expression was ness respectively. Immunohistochemistry and antibody-depen- found to be an independent predictor of poor disease-free survival dent cell cytotoxicity (ADCC), together with siRNA strategy, (P ¼ 0.008).
    [Show full text]
  • Network Assessment of Demethylation Treatment in Melanoma: Differential Transcriptome-Methylome and Antigen Profile Signatures
    RESEARCH ARTICLE Network assessment of demethylation treatment in melanoma: Differential transcriptome-methylome and antigen profile signatures Zhijie Jiang1☯, Caterina Cinti2☯, Monia Taranta2, Elisabetta Mattioli3,4, Elisa Schena3,5, Sakshi Singh2, Rimpi Khurana1, Giovanna Lattanzi3,4, Nicholas F. Tsinoremas1,6, 1 Enrico CapobiancoID * a1111111111 1 Center for Computational Science, University of Miami, Miami, FL, United States of America, 2 Institute of Clinical Physiology, CNR, Siena, Italy, 3 CNR Institute of Molecular Genetics, Bologna, Italy, 4 IRCCS Rizzoli a1111111111 Orthopedic Institute, Bologna, Italy, 5 Endocrinology Unit, Department of Medical & Surgical Sciences, Alma a1111111111 Mater Studiorum University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy, 6 Department of a1111111111 Medicine, University of Miami, Miami, FL, United States of America a1111111111 ☯ These authors contributed equally to this work. * [email protected] OPEN ACCESS Abstract Citation: Jiang Z, Cinti C, Taranta M, Mattioli E, Schena E, Singh S, et al. (2018) Network assessment of demethylation treatment in Background melanoma: Differential transcriptome-methylome and antigen profile signatures. PLoS ONE 13(11): In melanoma, like in other cancers, both genetic alterations and epigenetic underlie the met- e0206686. https://doi.org/10.1371/journal. astatic process. These effects are usually measured by changes in both methylome and pone.0206686 transcriptome profiles, whose cross-correlation remains uncertain. We aimed to assess at Editor: Roger Chammas, Universidade de Sao systems scale the significance of epigenetic treatment in melanoma cells with different met- Paulo, BRAZIL astatic potential. Received: June 20, 2018 Accepted: October 17, 2018 Methods and findings Published: November 28, 2018 Treatment by DAC demethylation with 5-Aza-2'-deoxycytidine of two melanoma cell lines Copyright: © 2018 Jiang et al.
    [Show full text]
  • A Stealth Cloak for Cancer Cells
    BMB Rep. 2021; 54(7): 344-355 BMB www.bmbreports.org Reports Invited Mini Review Mucin in cancer: a stealth cloak for cancer cells Dong-Han Wi1, Jong-Ho Cha2,3 & Youn-Sang Jung1,* 1Department of Life Science, Chung-Ang University, Seoul, 06974, 2Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212, 3Department of Biomedical Science, Program in Biomedical Science and Engineering, Graduate school, Inha University, Incheon 22212, Korea Mucins are high molecular-weight epithelial glycoproteins and mucinous colorectal carcinoma (MCC) (3). Since tumor growth are implicated in many physiological processes, including epit- sites induce inhospitable conditions for them to survive, helial cell protection, signaling transduction, and tissue home- mucins are suggested as an oncogenic microenvironment that ostasis. Abnormality of mucus expression and structure contri- avoids hypoxia, acidic, and other biological hurdles. The com- butes to biological properties related to human cancer progress- position and structure of mucins enable them to mimic the ion. Tumor growth sites induce inhospitable conditions. Many surface of tumor cells like the surface of normal epithelial cells kinds of research suggest that mucins provide a microenviron- (4). Additionally, the mucus layer captures growth factors or ment to avoid hypoxia, acidic, and other biological conditions cytokines, contributing to cell growth of the tumor. Alter- that promote cancer progression. Given that the mucus layer natively, these properties interfere with the interaction bet- captures growth factors or cytokines, we propose that mucin ween the immune system and tumor cells. Indeed, a high helps to ameliorate inhospitable conditions in tumor-growing concentration of soluble mucins downregulates the motility sites.
    [Show full text]
  • Quantigene Flowrna Probe Sets Currently Available
    QuantiGene FlowRNA Probe Sets Currently Available Accession No. Species Symbol Gene Name Catalog No. NM_003452 Human ZNF189 zinc finger protein 189 VA1-10009 NM_000057 Human BLM Bloom syndrome VA1-10010 NM_005269 Human GLI glioma-associated oncogene homolog (zinc finger protein) VA1-10011 NM_002614 Human PDZK1 PDZ domain containing 1 VA1-10015 NM_003225 Human TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) VA1-10016 NM_002276 Human KRT19 keratin 19 VA1-10022 NM_002659 Human PLAUR plasminogen activator, urokinase receptor VA1-10025 NM_017669 Human ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like VA1-10029 NM_017699 Human SIDT1 SID1 transmembrane family, member 1 VA1-10032 NM_000077 Human CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) VA1-10040 NM_003150 Human STAT3 signal transducer and activator of transcripton 3 (acute-phase response factor) VA1-10046 NM_004707 Human ATG12 ATG12 autophagy related 12 homolog (S. cerevisiae) VA1-10047 NM_000737 Human CGB chorionic gonadotropin, beta polypeptide VA1-10048 NM_001017420 Human ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) VA1-10050 NM_197978 Human HEMGN hemogen VA1-10051 NM_001738 Human CA1 Carbonic anhydrase I VA1-10052 NM_000184 Human HBG2 Hemoglobin, gamma G VA1-10053 NM_005330 Human HBE1 Hemoglobin, epsilon 1 VA1-10054 NR_003367 Human PVT1 Pvt1 oncogene homolog (mouse) VA1-10061 NM_000454 Human SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))
    [Show full text]
  • Digitalcommons@UNMC Regulation of the Transmembrane Mucin MUC4
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Fall 12-18-2015 Regulation of the transmembrane mucin MUC4 by Wnt/β-catenin in gastrointestinal cancers Priya Pai University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, and the Molecular Biology Commons Recommended Citation Pai, Priya, "Regulation of the transmembrane mucin MUC4 by Wnt/β-catenin in gastrointestinal cancers" (2015). Theses & Dissertations. 58. https://digitalcommons.unmc.edu/etd/58 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. i Regulation of the transmembrane mucin MUC4 by Wnt/β- catenin in gastrointestinal cancers By PRIYA PAI A DISSERTATION Presented to the Faculty of The University of Nebraska Graduate College In Partial Fulfillment of the Requirements For the Degree of Doctor of Philosophy Department of Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor Surinder K. Batra University of Nebraska Medical Center Omaha, Nebraska November, 2015 ii Regulation of the transmembrane mucin MUC4 by Wnt/β-catenin in gastrointestinal cancers Priya Pai, PhD. University of Nebraska Medical Center, 2015 Supervisor: Surinder K. Batra, PhD. The transmembrane mucin MUC4 is a high molecular weight glycoprotein that is expressed de novo in pancreatic ductal adenocarcinoma (PDAC). MUC4 has been shown to play a tumor-promoting role in malignancies such as PDAC, ovarian cancer and breast cancer.
    [Show full text]
  • And HPV18-Infected Early Stage Cervical Cancers and Normal
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Virology 331 (2005) 269–291 www.elsevier.com/locate/yviro Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy Alessandro D. Santina,*, Fenghuang Zhanb, Eliana Bignottia, Eric R. Siegelc, Stefania Cane´ a, Stefania Bellonea, Michela Palmieria, Simone Anfossia, Maria Thomasd, Alexander Burnetta, Helen H. Kaye, Juan J. Romana, Timothy J. O’Briena, Erming Tianb, Martin J. Cannonf, John Shaughnessy Jr.b, Sergio Pecorellig aDivision of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA bMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA cDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA dDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA eDepartment of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA fDepartment of Microbiology and Immunology, University of Arkansas, Little Rock, AR 72205, USA gDivision of Gynecologic Oncology, University of Brescia, Brescia, Italy Received 2 July 2004; returned to author for revision 18 August 2004; accepted 9 September 2004 Available online 21 November 2004 Abstract With the goal of identifying genes with a differential pattern of expression between invasive cervical carcinomas (CVX) and normal cervical keratinocytes (NCK), we used oligonucleotide microarrays to interrogate the expression of 14,500 known genes in 11 primary HPV16 and HPV18-infected stage IB–IIA cervical cancers and four primary normal cervical keratinocyte cultures.
    [Show full text]
  • A Dual Cis-Regulatory Code Links IRF8 to Constitutive and Inducible Gene Expression in Macrophages
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages Alessandra Mancino,1,3 Alberto Termanini,1,3 Iros Barozzi,1 Serena Ghisletti,1 Renato Ostuni,1 Elena Prosperini,1 Keiko Ozato,2 and Gioacchino Natoli1 1Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy; 2Laboratory of Molecular Growth Regulation, Genomics of Differentiation Program, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA The transcription factor (TF) interferon regulatory factor 8 (IRF8) controls both developmental and inflammatory stimulus-inducible genes in macrophages, but the mechanisms underlying these two different functions are largely unknown. One possibility is that these different roles are linked to the ability of IRF8 to bind alternative DNA sequences. We found that IRF8 is recruited to distinct sets of DNA consensus sequences before and after lipopolysaccharide (LPS) stimulation. In resting cells, IRF8 was mainly bound to composite sites together with the master regulator of myeloid development PU.1. Basal IRF8–PU.1 binding maintained the expression of a broad panel of genes essential for macrophage functions (such as microbial recognition and response to purines) and contributed to basal expression of many LPS-inducible genes. After LPS stimulation, increased expression of IRF8, other IRFs, and AP-1 family TFs enabled IRF8 binding to thousands of additional regions containing low-affinity multimerized IRF sites and composite IRF–AP-1 sites, which were not premarked by PU.1 and did not contribute to the basal IRF8 cistrome.
    [Show full text]
  • CRB3 Antibody (Center) Blocking Peptide Synthetic Peptide Catalog # Bp17560c
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CRB3 Antibody (Center) Blocking Peptide Synthetic peptide Catalog # BP17560c Specification CRB3 Antibody (Center) Blocking Peptide - CRB3 Antibody (Center) Blocking Peptide - Background Product Information This gene encodes a member of the Crumbs Primary Accession Q9BUF7 family ofproteins. This protein may play a role in epithelial cell polarityand is associated with tight junctions at the apical surface ofepithelial CRB3 Antibody (Center) Blocking Peptide - Additional Information cells. Alternate transcriptional splice variants,encoding different isoforms, have been characterized. [provided byRefSeq]. Gene ID 92359 CRB3 Antibody (Center) Blocking Peptide - Other Names References Protein crumbs homolog 3, CRB3 Pardossi-Piquard, R., et al. Biochemistry Format 46(48):13704-13710(2007)Fan, S., et al. J. Cell Peptides are lyophilized in a solid powder Biol. 178(3):387-398(2007)Fogg, V.C., et al. J. format. Peptides can be reconstituted in solution using the appropriate buffer as Cell. Sci. 118 (PT 13), 2859-2869 (2005) needed. :Lemmers, C., et al. Mol. Biol. Cell 15(3):1324-1333(2004)Roh, M.H., et al. J. Cell. Storage Sci. 116 (PT 14), 2895-2906 (2003) : Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. CRB3 Antibody (Center) Blocking Peptide - Protein Information Name CRB3 (HGNC:20237) Function Involved in the establishment of cell polarity in mammalian epithelial cells (PubMed:<a href="http://www.uniprot.org/c itations/12771187" target="_blank">12771187</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14718572" target="_blank">14718572</a>).
    [Show full text]
  • Knock-Out Validated Antibodies from Cloud-Clone Cat.No
    Knock-out validated antibodies from Cloud-Clone Cat.No. Target PAA778Hu01 B-Cell Leukemia/Lymphoma 2 (Bcl2) PAL763Hu01 Myxovirus Resistance 1 (MX1) PAB698Hu01 Lactate Dehydrogenase B (LDHB) PAA009Hu01 Angiopoietin 2 (ANGPT2) PAA849Ra01 Glycogen Phosphorylase, Liver (PYGL) PAA153Hu01 Alpha-Fetoprotein (aFP) PAF460Hu01 Folate Receptor 1, Adult (FOLR1) PAB233Hu01 Cyclin Dependent Kinase 4 (CDK4) PAA150Hu04 Carcinoembryonic Antigen (CEA) PAB905Hu01 Interleukin 7 Receptor (IL7R) PAC823Hu01 Thymidine Kinase 1, Soluble (TK1) PAH838Hu01 Isocitrate Dehydrogenase 2, mitochondrial (IDH2) PAK078Mu01 Fas Associating Death Domain Containing Protein (FADD) PAA537Hu01 Enolase, Neuron Specific (NSE) PAA651Hu01 Hyaluronan Binding Protein 1 (HABP1) PAB215Hu02 Fibrinogen Beta (FGb) PAB769Hu01 S100 Calcium Binding Protein A6 (S100A6) PAB231Hu01 Keratin 18 (KRT18) PAH839Hu01 Isocitrate Dehydrogenase 1, Soluble (IDH1) PAE748Hu01 Karyopherin Alpha 2 (KPNa2) PAB081Hu02 Heat Shock 70kDa Protein 1A (HSPA1A) PAA778Mu01 B-Cell Leukemia/Lymphoma 2 (Bcl2) PAA853Hu03 Caspase 8 (CASP8) PAA399Mu01 High Mobility Group Protein 1 (HMG1) PAA303Mu01 Galectin 3 (GAL3) PAA537Mu02 Enolase, Neuron Specific (NSE) PAA994Ra01 Acid Phosphatase 1 (ACP1) PAB083Ra01 Superoxide Dismutase 2, Mitochondrial (SOD2) PAB449Mu01 Enolase, Non Neuronal (NNE) PAA376Mu01 Actinin Alpha 2 (ACTN2) PAA553Ra01 Matrix Metalloproteinase 9 (MMP9) PAA929Bo01 Retinol Binding Protein 4, Plasma (RBP4) PAA491Ra02 Keratin 2 (KRT2) PAC025Hu01 Keratin 8 (KRT8) PAB231Mu01 Keratin 18 (KRT18) PAC598Hu03 Vanin 1 (VNN1)
    [Show full text]